Soker S, Goldstaub D, Svahn C M, Vlodavsky I, Levi B Z, Neufeld G
Department of Biology, Technion, Israel Institute of Technology, Haifa.
Biochem Biophys Res Commun. 1994 Sep 15;203(2):1339-47. doi: 10.1006/bbrc.1994.2329.
The binding of the 165 amino-acid form of vascular endothelial growth factor (VEGF165) to the VEGF receptors of vascular endothelial cells was potentiated by heparin and heparan-sulfate, but not by other glycosaminoglycans. Heparin fragments of 16-18 sugar units inhibited the binding of 125I-VEGF165 to VEGF receptors, while fragments larger than 22 sugar units potentiated the binding. Over-sulfated heparin was a better potentiator of 125I-VEGF165 binding than native heparin. O-desulfated and N-desulfated heparins potentiated the binding to a lesser extent than native heparin. Heparin and N-desulfated heparin efficiently inhibited the binding of 125I-VEGF165 to alpha 2-macroglobulin, but surprisingly, O-desulfated heparin was an ineffective inhibitor. Since alpha 2-macroglobulin does not bind heparin, it follows that VEGF165 does not bind O-desulfated heparin efficiently. These results suggest that the mechanism by which heparin modulates the binding of VEGF165 to the VEGF receptors may require an interaction with cell surface heparin binding molecules.
血管内皮生长因子165氨基酸形式(VEGF165)与血管内皮细胞的VEGF受体的结合可被肝素和硫酸乙酰肝素增强,但其他糖胺聚糖则无此作用。16 - 18个糖单位的肝素片段可抑制125I - VEGF165与VEGF受体的结合,而大于22个糖单位的片段则增强结合。过度硫酸化的肝素比天然肝素更能增强125I - VEGF165的结合。O - 去硫酸化和N - 去硫酸化的肝素增强结合的程度低于天然肝素。肝素和N - 去硫酸化肝素能有效抑制125I - VEGF165与α2 - 巨球蛋白的结合,但令人惊讶的是,O - 去硫酸化肝素是无效抑制剂。由于α2 - 巨球蛋白不结合肝素,因此VEGF165不能有效地结合O - 去硫酸化肝素。这些结果表明,肝素调节VEGF165与VEGF受体结合的机制可能需要与细胞表面肝素结合分子相互作用。